Ongoing efforts to develop IDE activators and insulin-sensitizing agents aim to alleviate amyloid burden and delay cognitive decline, positioning IDE-centered interventions as a critical component of future AD treatment in the obesity context. This evidence concerns the gene INS and Alzheimer disease.